Clinical Trials Browser

Interventional × 2-Propanol × 90 days × Clear all

NCT03728335 2026-03-13

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic